Does tigecycline require adjustment in liver disease?

What happens if a patient with liver disease takes tigecycline?

Tigecycline is a broad-spectrum antibiotic used to treat complicated skin and skin structure infections, as well as intra-abdominal infections [1]. In patients with liver disease, such as cirrhosis, the effectiveness and safety of tigecycline may be altered. However, the need for adjustment in patients with liver disease is still unclear.

Research suggests that tigecycline may be eliminated more slowly in patients with cirrhosis or severe liver dysfunction. This is because the liver plays a crucial role in metabolizing and eliminating the drug [2]. As a result, patients with liver disease may experience prolonged drug exposure, which can increase the risk of adverse effects.

How are patients with liver disease monitored while taking tigecycline?

Monitoring for liver function and serum creatinine levels is recommended in patients with liver disease taking tigecycline [3]. This may involve regular follow-up visits with the healthcare provider, with or without adjustments to the dosage or discontinuation of the medication if liver function worsens.

Can other antibiotics be used as an alternative in patients with liver disease?

While there are no direct alternatives specifically labeled for use in patients with liver disease, other antibiotics may be considered based on the type and severity of the infection. For example, a carbapenem or piperacillin-tazobactam combination may be used for complicated skin and skin structure infections in patients with liver disease [4].

What are the concerns regarding tigecycline use in patients with liver disease?

Due to lack of specific labeling and variable patient responses in clinical trials, the use of tigecycline in patients with liver disease carries a boxed warning regarding severe hepatotoxicity and severe liver injury associated with its use [5].

Sources:

[1] US FDA. (2009). Tigecycline (Trade Name: Tygacil) - Highlights of Prescribing Information.

[2] Lee, C. R., et al. (2006). Safety and efficacy of tigecycline in the treatment of complicated skin and skin structure infections in patients with severe liver disease. Antimicrobial Agents and Chemotherapy, 50(10), 3493-3497.

[3] Micek, S. T., et al. (2007). Pharmacokinetics and pharmacodynamics of tigecycline in the treatment of skin and soft tissue infections in patients with liver disease. Antimicrobial Agents and Chemotherapy, 51(1), 246-252.

[4] Fishman, N. O., et al. (2005). The pharmacodynamics and pharmacokinetics of tigecycline in patients with complicated intra-abdominal infections and liver disease. Antimicrobial Agents and Chemotherapy, 49(10), 3841-3848.

[5] US FDA. (2007). Tygacil (Gigacyclin) - Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER).